Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Occamy-1.0: Open Pareto-frontier 35B Intelligence for Co-work
arXiv:2609.11977v1 Announce Type: new Abstract: Co-work agents execute complex workflows that combine information gathering, tool use, coding, and file manipulation across many model invocations. Because cost and latency accumulate over the full episode, their practical value depends not only on peak capability but also on how efficiently that capability is delivered. Yet many steps in everyday work emphasize state tracking, coordination, recovery, and follow-through rather than frontier-scale
-
Nature Biotechnology - Issue - nature.com science feeds
-
An engineered nanopore identifies saccharides, amino acids, peptides and ribonucleotides
Nature Biotechnology, Published online: 14 September 2026; doi:10.1038/s41587-026-03308-9Modified nanopore simultaneously identifies diverse biomolecules and their modifications.
An engineered nanopore identifies saccharides, amino acids, peptides and ribonucleotides
Nature Biotechnology, Published online: 14 September 2026; doi:10.1038/s41587-026-03308-9
Modified nanopore simultaneously identifies diverse biomolecules and their modifications.-
Omics In Lung
-
Advanced and underlying therapeutic strategies in transformed small cell lung cancer
Front Med (Lausanne). 2026 Aug 27;13:1865050. doi: 10.3389/fmed.2026.1865050. eCollection 2026.ABSTRACTTransformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9-13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy
Advanced and underlying therapeutic strategies in transformed small cell lung cancer
Front Med (Lausanne). 2026 Aug 27;13:1865050. doi: 10.3389/fmed.2026.1865050. eCollection 2026.
ABSTRACT
Transformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9-13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy remains the gold standard for confirming histologic transformation, whereas molecular profiling and liquid biopsy may facilitate early detection and longitudinal disease monitoring. Platinum-etoposide remains the most commonly used clinical standard after transformation, but its benefit is typically transient and durable disease control remains uncommon. Continuation of EGFR tyrosine kinase inhibitors combined with chemotherapy may prolong progression-free survival in selected patients but has not consistently improved overall survival. Anti-angiogenic therapy, particularly anlotinib, and chemo-immunotherapy have shown encouraging activity in selected patients, while emerging strategies targeting DLL3, MYC, SOX2, and epigenetic regulators may broaden the therapeutic landscape. Prospective studies integrating repeat tissue sampling, comprehensive genomic profiling, biomarker-guided patient stratification, pharmacogenomics, functional drug-sensitivity testing where feasible, and integrated multi-omics approaches are needed to advance molecularly guided and individualized treatment for T-SCLC.
PMID:42724635 | PMC:PMC13560167 | DOI:10.3389/fmed.2026.1865050